Cost‐effectiveness of inpatient and intensive outpatient treatment of rheumatoid arthritis. A randomized, controlled trial

Inpatient and outpatient rehabilitation for patients with rheumatoid arthritis: a clinical and economic assessment

“…The higher inpatient costs found in this study are consistent with results from other studies which found that inpatient costs were higher than outpatient costs 5,6,8,10,12 .…”

“…However, the studies had many methodological problems, including lack of randomisation [3][4][5][6] and lack of concealment of assessors 3-5 , 7 . Other studies [8][9][10] investigating intensive inpatient and outpatient care found the two settings to be equally effective 9,10 , with one study 8 concluded that intensive inpatient care supplemented with follow-up outpatient care was more effective than inpatient care alone.…”

Aproximación al coste del tratamiento farmacológico en la artritis reumatoide en España

“…Para el uso de un segundo FARAL asociado, el gasto medio mensual fue de 2.287,93 pesetas (158-38.476 pesetas; DS: 1.053,67), equivalente a 13,75 . El gasto medio para un tercer FARAL asociado fue de 2.400 pesetas (14,42 ). El reparto por fármacos como primer inductor de remisión ha sido de un 76,6% de utilización de metotrexato, seguido de un 14,2% de utilización de cloroquina, un 2,8% para auranofin, un 1,4% para el uso de leflunomida y menos del 1% para D-penicilamina o azatioprina.…”

Economics and arthritis

“…Despite their inability to blind the evaluators to the type of intervention received by the patients, they found a statistically and clinically important improvement in the hospitalized group (22). Clearly, they do not know what it is about hospitalization that results in an increased benefit.…”